Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

By

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

By

United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.

Segmental Pulmonary Hypertension: Management of New Classification

Segmental Pulmonary Hypertension: Management of New Classification

By

Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.

Implantable System for Remodulin Approved for Patients With PAH

Implantable System for Remodulin Approved for Patients With PAH

By

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.

VTE Increases Risk for Chronic Thromboembolic Pulmonary Hypertension

VTE Increases Risk for Chronic Thromboembolic Pulmonary Hypertension

By

A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

By

Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.

Neopterin as a Potential Biomarker in PAH and Inoperable CTEPH

Neopterin as a Potential Biomarker in PAH and Inoperable CTEPH

By

Neopterin was predictive of clinical deterioration in patients with pulmonary arterial hypertension and inoperable CTEPH.

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

By

Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.

Pregnancy in Pulmonary Arterial Hypertension: Improved Patient Counseling Needed

Pregnancy in Pulmonary Arterial Hypertension: Improved Patient Counseling Needed

By

Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.

PAH in Congenital Heart Disease: Challenges and Advances

PAH in Congenital Heart Disease: Challenges and Advances

By

Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.

Worsening Shortness of Breath in Patient With Hypertension, Afib

Worsening Shortness of Breath in Patient With Hypertension, Afib

By

A 72-year-old man with hypertension and paroxysmal atrial fibrillation presents to the emergency department because he has been experiencing worsening shortness of breath.

Age-Obesity Interaction in Pulmonary Arterial Hypertension

Age-Obesity Interaction in Pulmonary Arterial Hypertension

The interaction of age and obesity with respect to survival in pulmonary arterial hypertension showed an increased risk for mortality in young adults who were morbidly obese.

PAH in Systemic Sclerosis Increases Risk for Early Mortality

PAH in Systemic Sclerosis Increases Risk for Early Mortality

By

The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.

CTEPH Increases Risk for Sleep Disordered Breathing

CTEPH Increases Risk for Sleep Disordered Breathing

By

Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

By

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

Clinical Trials in PAH: Interpreting Risk Reduction With Caution

Clinical Trials in PAH: Interpreting Risk Reduction With Caution

By

Researchers raise issues regarding interpretation of clinical trial results in the field of pulmonary arterial hypertension.

PAH Pulmonary Hemodynamics Improved With Optimized Iloprost Delivery

PAH Pulmonary Hemodynamics Improved With Optimized Iloprost Delivery

By

Researchers modified the inhalation technique of iloprost in a patient with pulmonary arterial hypertension by attaching a nasal cannula to the inhalator's inlet port, shortening the administration duration.

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

By

The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.

Arrhythmia Associated With Higher Mortality in Congenitial Heart Disease-Related PAH

Arrhythmia Associated With Higher Mortality in Congenitial Heart Disease-Related PAH

By

Arrhythmia was a significant predictor of mortality in adult patients with congenital heart disease and pulmonary arterial hypertension.

Right Ventricular Stroke Work Effective Biomarker in Pediatric PAH

Right Ventricular Stroke Work Effective Biomarker in Pediatric PAH

By

Clinical worsening in pediatric pulmonary arterial hypertension may be predicted using right ventricular stroke work indexed by ejection fraction.

Composite Echo Score Predicts PH in Interstitial Lung Disease

Composite Echo Score Predicts PH in Interstitial Lung Disease

By

The variables for the stepwise echocardiographic score included right ventricular systolic pressure, early pulmonary regurgitation gradient, right atrial area size, tricuspid regurgitation velocity, left ventricle eccentricity index, and right ventricle fractional area change.

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

By

There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.

Poor Subpleural Perfusion May Predict Balloon Pulmonary Angioplasty Failure

Poor Subpleural Perfusion May Predict Balloon Pulmonary Angioplasty Failure

By

Poor subpleural perfusion in patients with nonoperable chronic thromboembolic pulmonary hypertension may predict balloon pulmonary angioplasty failure.

Metformin May Benefit Pulmonary Hypertension Associated With HFpEF, But Not PAH

Metformin May Benefit Pulmonary Hypertension Associated With HFpEF, But Not PAH

By

Although metformin prevented the development of PAH in hypoxia and monocrotalinerat models and reversed PAH in SU5416/hypoxia rats, it failed to reverse pulmonary pressures and vascular remodeling in mice with SU5416/hypoxia-induced PAH.

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

By

Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus in pulmonary arterial hypertension should be considered separate diseases.

PAH-SYMPACT<sup>®</sup>: A Reliable Instrument for PAH Symptom Assessment

PAH-SYMPACT®: A Reliable Instrument for PAH Symptom Assessment

By

The Pulmonary Arterial Hypertension-Symptoms and Impact questionnaire has good psychometric properties and can be administered in clinical practice.

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

By

Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.

Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

Survival Rates With Parenteral Prostanoids in Pulmonary Arterial Hypertension

By

In patients with pulmonary arterial hypertension who were treated with a parenteral prostanoid, survival was linked with the number of guideline-recommended lower-risk and higher-risk criteria attained.

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

By

Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

By

Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.

Sign Up for Free e-newsletters